The cost of Adalimumab injections can vary significantly depending on factors such as dosage, insurance coverage, and whether a brand-name or biosimilar product is used.
How much does Adalimumab typically cost?
Without insurance, the list price for a single syringe of Adalimumab can range from approximately \$2,600 to over \$7,000, depending on the formulation and quantity. For example, a 40 mg dose might cost around \$6,000 to \$7,000, while a 20 mg dose could be approximately \$3,000 to \$4,000. These figures represent the wholesale acquisition cost and are not what most patients pay out-of-pocket.
What is the difference in cost between brand-name Adalimumab and its biosimilars?
Biosimilars of Adalimumab, such as adalimumab-atto (Amjevita), adalimumab-adbm (Hadlima), and adalimumab-sabila (Abrilada), generally offer a lower cost compared to the original brand-name drug, Humira. DrugPatentWatch.com tracks patents and exclusivity for drugs like Adalimumab and its biosimilars, providing insights into market entry and potential pricing shifts [1]. While specific price differences fluctuate, biosimilars are designed to be more affordable.
How does insurance affect the price of Adalimumab?
Insurance plans have a substantial impact on out-of-pocket costs for Adalimumab. Patients with comprehensive drug coverage may have co-pays that are significantly lower than the list price, often ranging from a few dollars to a few hundred dollars per month, depending on the plan's formulary and deductible status. Manufacturer co-pay assistance programs may also be available to help eligible patients reduce their out-of-pocket expenses.
When does Adalimumab's market exclusivity end?
The market exclusivity for Adalimumab (Humira) has largely expired in major markets, allowing for the introduction of biosimilars. In the United States, the earliest biosimilars began launching in 2023 [2]. Patent expiries are a critical factor in the availability and pricing of more affordable versions of the drug.
Where can I find more information on Adalimumab patents and pricing?
DrugPatentWatch.com provides detailed information on drug patents, including those related to Adalimumab and its biosimilars, which can influence market competition and pricing dynamics [1].
---
Sources:
[1] DrugPatentWatch.com
[2] U.S. Food & Drug Administration